Rate of Tumor Growth Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation in Patients Beyond Milan or UCSF Criteria
Abstract Background It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for...
Saved in:
Published in | Transplantation proceedings Vol. 43; no. 10; pp. 3813 - 3818 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier Inc
01.12.2011
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract Background It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC). Methods We identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr3 , where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed. Results Ninety-two patients were included in the study. The median follow-up was 19.5 (range 10.7–30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P = .001), poorly differentiated tumors (HR 13; P = .039), the presence of microvascular invasion (HR 7.9; P = .001), higher TTV (HR 1.03; P < .001), and faster tumor growth (HR 1.09; P < .001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm3 /mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth <1.61 cm3 /mo experienced less recurrence (11% vs 58%; P = .023) than those beyond the Milan criteria with tumor growth >1.61 cm3 /mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria. Conclusions Patients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome. |
---|---|
AbstractList | It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC).
We identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr3, where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed.
Ninety-two patients were included in the study. The median follow-up was 19.5 (range 10.7-30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P=.001), poorly differentiated tumors (HR 13; P=.039), the presence of microvascular invasion (HR 7.9; P=.001), higher TTV (HR 1.03; P<.001), and faster tumor growth (HR 1.09; P<.001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm3/mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth<1.61 cm3/mo experienced less recurrence (11% vs 58%; P=.023) than those beyond the Milan criteria with tumor growth>1.61 cm3/mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria.
Patients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome. It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC). We identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr 3, where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed. Ninety-two patients were included in the study. The median follow-up was 19.5 (range 10.7–30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P = .001), poorly differentiated tumors (HR 13; P = .039), the presence of microvascular invasion (HR 7.9; P = .001), higher TTV (HR 1.03; P < .001), and faster tumor growth (HR 1.09; P < .001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm 3/mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth <1.61 cm 3/mo experienced less recurrence (11% vs 58%; P = .023) than those beyond the Milan criteria with tumor growth >1.61 cm 3/mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria. Patients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome. BACKGROUNDIt is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC).METHODSWe identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr3, where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed.RESULTSNinety-two patients were included in the study. The median follow-up was 19.5 (range 10.7-30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P=.001), poorly differentiated tumors (HR 13; P=.039), the presence of microvascular invasion (HR 7.9; P=.001), higher TTV (HR 1.03; P<.001), and faster tumor growth (HR 1.09; P<.001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm3/mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth<1.61 cm3/mo experienced less recurrence (11% vs 58%; P=.023) than those beyond the Milan criteria with tumor growth>1.61 cm3/mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria.CONCLUSIONSPatients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome. Abstract Background It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low risk of tumor recurrence after liver transplantation (LT). To assess the rate of tumor growth as selection criteria for LT in patients with hepatocellular carcinoma (HCC). Methods We identified all patients who underwent LT for HCC in our institution from 2002 to 2008. Total tumor volume (TTV) was calculated as the sum of the volumes of all tumors on pretransplantation imaging [(4/3)πr3 , where r is the maximum radius of each HCC]. The rate of tumor growth was calculated as per-month change in TTV on sequential pretransplantation imaging before any locoregional therapy. A Kaplan-Meier plot was constructed and Cox regression analysis performed. Results Ninety-two patients were included in the study. The median follow-up was 19.5 (range 10.7–30.7) months during which 12 patients (13%) experienced recurrence of HCC. Twenty-four patients (26%) had HCC beyond the Milan criteria, and the overall survival rate of the entire group was 72%. Higher pre-LT alpha-fetoprotein (hazard ratio [HR] 1.01; P = .001), poorly differentiated tumors (HR 13; P = .039), the presence of microvascular invasion (HR 7.9; P = .001), higher TTV (HR 1.03; P < .001), and faster tumor growth (HR 1.09; P < .001) were significantly associated with the risk of recurrence. A cutoff value of tumor growth of 1.61 cm3 /mo was chosen on the basis of the risk of recurrence with the use of a receiver operating characteristic curve. Patients beyond the Milan criteria with tumor growth <1.61 cm3 /mo experienced less recurrence (11% vs 58%; P = .023) than those beyond the Milan criteria with tumor growth >1.61 cm3 /mo. Similarly, rate of tumor growth predicted HCC recurrence in those beyond the University of California of San Francisco (UCSF) criteria. Conclusions Patients with slowly growing tumor who would be currently excluded from LT because tumor burden exceeds traditional Milan and UCSF criteria may have a favorable posttransplantation outcome. |
Author | Aucejo, F Hanouneh, I.A Macaron, C Zein, N.N Lopez, R |
Author_xml | – sequence: 1 fullname: Hanouneh, I.A – sequence: 2 fullname: Macaron, C – sequence: 3 fullname: Lopez, R – sequence: 4 fullname: Aucejo, F – sequence: 5 fullname: Zein, N.N |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25344251$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22172852$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUk1vEzEQtVARTQt_AVlIiFOCP5MsB6SypS1SEFWbni3HOyscNnawvUX5C_3VzDapQJy42GPNmzfj9-aEHIUYgJA3nE0449P360lJNuRtig6gmQjG-YRVE6bkMzLi85kci6mQR2TEmOJjLpU-Jic5rxm-hZIvyLEQfCbmWozIw40tQGNLl_0mJnqZ4q_ynV4naLwrmd6A61OC4B4xV7C1BZt2Xd_ZRGubnA9xY-lZWyDRhb_Hc_k4W2dDscXHQH2g1xhBQLpPsIuhoV89pim2u6tvL2idPFZ7-5I8b22X4dXhPiV3F5-X9dV48e3yS322GDs1VWUsW6lXSopGMzdX80brSvEZd8qttGWKNU5q7aZSOOfAVis5m7dN1bRTjAVDdU7Juz0vCvizh1zMxufhUzZA7LOpOK8040Ij8sMe6VLMOUFrtslvbNoZzsxghVmbv60wgxWGVQatwOLXhzb9aoO5p9In7RHw9gCw2dmuRSLn8x-clkoJzRF3vscBinLvIZns_GBJ4xO4Ypro_2-ej__QuM4Hj51_wA7yOvYpoOyGmywMM7fD8gy7w5EY94nJ39SfxlQ |
CODEN | TRPPA8 |
CitedBy_id | crossref_primary_10_1007_s11901_012_0156_0 crossref_primary_10_1016_j_cld_2014_05_013 crossref_primary_10_1016_j_jvir_2014_09_012 crossref_primary_10_1016_j_iliver_2024_100077 crossref_primary_10_1016_j_jviscsurg_2017_12_001 crossref_primary_10_1097_MCG_0b013e318286ff8e crossref_primary_10_1016_S1499_3872_15_60349_6 crossref_primary_10_3748_wjg_v22_i12_3325 crossref_primary_10_3892_etm_2017_4748 crossref_primary_10_1016_j_jchirv_2017_02_006 crossref_primary_10_1007_s11605_013_2140_6 crossref_primary_10_1016_j_surg_2016_08_049 crossref_primary_10_1016_j_transproceed_2014_10_044 crossref_primary_10_1136_gutjnl_2014_308483 crossref_primary_10_1093_bjsopen_zrab130 |
Cites_doi | 10.1053/j.gastro.2007.04.061 10.1053/jlts.2002.34923 10.1016/j.transproceed.2010.10.012 10.1002/lt.21484 10.1097/01.TP.0000152801.82734.74 10.1053/jhep.2001.23561 10.1038/nm1377 10.1056/NEJM199903113401001 10.1002/hep.20933 10.1056/NEJMoa0804525 10.1158/1078-0432.CCR-07-0523 10.1056/NEJM199603143341104 10.3322/canjclin.55.2.74 10.1097/00000658-199810000-00005 |
ContentType | Journal Article |
Copyright | 2011 2015 INIST-CNRS Copyright © 2011. Published by Elsevier Inc. |
Copyright_xml | – notice: 2011 – notice: 2015 INIST-CNRS – notice: Copyright © 2011. Published by Elsevier Inc. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.transproceed.2011.09.043 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2623 |
EndPage | 3818 |
ExternalDocumentID | 10_1016_j_transproceed_2011_09_043 22172852 25344251 S0041134511012620 1_s2_0_S0041134511012620 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Ohio |
GeographicLocations_xml | – name: Ohio |
GroupedDBID | - 08R 0R 1 1- 123 1B1 1P 1~. 1~5 29Q 3O- 4.4 457 4G. 53G 55 5RE 5VS 7-5 71M 8P AABNK AACTN AAEDT AAIAV AAIKJ AAKOC AALMO AALRI AAOAW AAPBV AAQFI AAQXK AAXUO ABBQC ABFLS ABFRF ABLJU ABLVK ABMAC ABMZM ABOCM ABPIF ABPTK ABQIS ABWYI ABXDB ABYKQ ACDAQ ACGFO ACIUM ACRLP ADALY ADBBV ADEZE AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FO G- G-Q GBLVA GJ HVGLF HZ IHE IPNFZ J1W J5H K K-O KOM L7B LCYCR M M41 MO0 N9A O-L O9- OAUVE OK- OW- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K UDS WH7 X7M XPP Y6R Z5R ZA5 ZGI ZXP --- --K --M .1- .55 .FO .GJ .~1 0R~ 1P~ 8P~ AAEDW ABJNI ADMUD AHPSJ AXJTR EFLBG FYGXN HZ~ ~G- AAUGY IQODW AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c464t-3f35b432d50c848d5594171c4cb5a040dc355c632cccea9b378fd9df6a9b20873 |
IEDL.DBID | .~1 |
ISSN | 0041-1345 |
IngestDate | Fri Aug 16 07:46:21 EDT 2024 Thu Sep 26 18:56:58 EDT 2024 Sat Sep 28 08:02:12 EDT 2024 Sun Oct 22 16:04:48 EDT 2023 Fri Feb 23 02:36:10 EST 2024 Thu Aug 18 17:13:44 EDT 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | Human Relapse Digestive system Liver Rate Prediction Hepatic disease Hepatocellular carcinoma Patient Malignant tumor Homotransplantation Medicine Liver cancer Treatment Tumor growth Criterion Surgery Digestive diseases Graft Predictive factor Cancer Liver transplantation |
Language | English |
License | CC BY 4.0 Copyright © 2011. Published by Elsevier Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c464t-3f35b432d50c848d5594171c4cb5a040dc355c632cccea9b378fd9df6a9b20873 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 22172852 |
PQID | 911950125 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_911950125 crossref_primary_10_1016_j_transproceed_2011_09_043 pubmed_primary_22172852 pascalfrancis_primary_25344251 elsevier_sciencedirect_doi_10_1016_j_transproceed_2011_09_043 elsevier_clinicalkeyesjournals_1_s2_0_S0041134511012620 |
PublicationCentury | 2000 |
PublicationDate | 2011-12-01 |
PublicationDateYYYYMMDD | 2011-12-01 |
PublicationDate_xml | – month: 12 year: 2011 text: 2011-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Amsterdam |
PublicationPlace_xml | – name: Amsterdam – name: United States |
PublicationTitle | Transplantation proceedings |
PublicationTitleAlternate | Transplant Proc |
PublicationYear | 2011 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | El-Serag, Mason (bib3) 1999; 340 Klintmalm (bib9) 1998; 228 Lee, Heo, Libbrecht (bib13) 2006; 12 Sotiropoulos, Malago, Molmenti (bib15) 2005; 79 Bruix, Sherman (bib5) 2005; 42 Macaron, Hanouneh, Lopez (bib17) 2010; 42 Parkin, Bray, Ferlay, Pisani (bib1) 2005; 55 Hoshida, Villanueva, Kobayashi (bib11) 2008; 359 Freeman, Mithoefer, Ruthazer (bib16) 2006; 6 Lovet, Burroughs, Bruix (bib4) 2003; 362 Jiang, Gusev, Aderca (bib12) 2008; 14 Yao, Bass, Nikolai (bib7) 2002; 8 Mazzaferro, Regalia, Doci (bib6) 1996; 334 Bruix, Sherman (bib14) 2005; 42 Toso, Trotter, Wei (bib8) 2008; 14 Jonas, Bechstein, Steinmüller (bib10) 2001; 33 El-Serag, Rudolph (bib2) 2007; 132 Jiang (10.1016/j.transproceed.2011.09.043_bib12) 2008; 14 Bruix (10.1016/j.transproceed.2011.09.043_bib14) 2005; 42 Lovet (10.1016/j.transproceed.2011.09.043_bib4) 2003; 362 Parkin (10.1016/j.transproceed.2011.09.043_bib1) 2005; 55 Klintmalm (10.1016/j.transproceed.2011.09.043_bib9) 1998; 228 El-Serag (10.1016/j.transproceed.2011.09.043_bib2) 2007; 132 Yao (10.1016/j.transproceed.2011.09.043_bib7) 2002; 8 Bruix (10.1016/j.transproceed.2011.09.043_bib5) 2005; 42 Freeman (10.1016/j.transproceed.2011.09.043_bib16) 2006; 6 Toso (10.1016/j.transproceed.2011.09.043_bib8) 2008; 14 Macaron (10.1016/j.transproceed.2011.09.043_bib17) 2010; 42 Lee (10.1016/j.transproceed.2011.09.043_bib13) 2006; 12 Sotiropoulos (10.1016/j.transproceed.2011.09.043_bib15) 2005; 79 Hoshida (10.1016/j.transproceed.2011.09.043_bib11) 2008; 359 Jonas (10.1016/j.transproceed.2011.09.043_bib10) 2001; 33 El-Serag (10.1016/j.transproceed.2011.09.043_bib3) 1999; 340 Mazzaferro (10.1016/j.transproceed.2011.09.043_bib6) 1996; 334 |
References_xml | – volume: 42 start-page: 1208 year: 2005 ident: bib14 article-title: Management of hepatocellular carcinoma publication-title: Hepatology contributor: fullname: Sherman – volume: 42 start-page: 4585 year: 2010 ident: bib17 article-title: Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria publication-title: Transplant Proc contributor: fullname: Lopez – volume: 55 start-page: 74 year: 2005 ident: bib1 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin contributor: fullname: Pisani – volume: 79 start-page: 483 year: 2005 ident: bib15 article-title: Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? publication-title: Transplantation contributor: fullname: Molmenti – volume: 8 start-page: 873 year: 2002 ident: bib7 article-title: Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list publication-title: Liver Transpl contributor: fullname: Nikolai – volume: 14 start-page: 1107 year: 2008 ident: bib8 article-title: Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma publication-title: Liver Transpl contributor: fullname: Wei – volume: 14 start-page: 419 year: 2008 ident: bib12 article-title: Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival publication-title: Clin Cancer Res contributor: fullname: Aderca – volume: 6 start-page: 350 year: 2006 ident: bib16 article-title: Staging of hepatocellular cancer (HCC) before liver transplantation is suboptimal publication-title: Am J Transplant contributor: fullname: Ruthazer – volume: 132 start-page: 2557 year: 2007 ident: bib2 article-title: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis publication-title: Gastroenterology contributor: fullname: Rudolph – volume: 42 start-page: 1208 year: 2005 ident: bib5 article-title: Management of hepatocellular carcinoma publication-title: Hepatology contributor: fullname: Sherman – volume: 33 start-page: 1080 year: 2001 ident: bib10 article-title: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis publication-title: Hepatology contributor: fullname: Steinmüller – volume: 359 start-page: 1995 year: 2008 ident: bib11 article-title: Gene expression in fixed tissues and outcome in hepatocellular carcinoma publication-title: N Engl J Med contributor: fullname: Kobayashi – volume: 12 start-page: 410 year: 2006 ident: bib13 article-title: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells publication-title: Nat Med contributor: fullname: Libbrecht – volume: 362 start-page: 1907 year: 2003 ident: bib4 article-title: Hepatocellularcarcinoma publication-title: Lancet contributor: fullname: Bruix – volume: 228 start-page: 479 year: 1998 ident: bib9 article-title: Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome publication-title: Ann Surg contributor: fullname: Klintmalm – volume: 334 start-page: 693 year: 1996 ident: bib6 article-title: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis publication-title: N Engl J Med contributor: fullname: Doci – volume: 340 start-page: 745 year: 1999 ident: bib3 article-title: Rising incidence of hepatocellular carcinoma in the United States publication-title: N Engl J Med contributor: fullname: Mason – volume: 132 start-page: 2557 year: 2007 ident: 10.1016/j.transproceed.2011.09.043_bib2 article-title: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.04.061 contributor: fullname: El-Serag – volume: 8 start-page: 873 year: 2002 ident: 10.1016/j.transproceed.2011.09.043_bib7 article-title: Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list publication-title: Liver Transpl doi: 10.1053/jlts.2002.34923 contributor: fullname: Yao – volume: 6 start-page: 350 issue: Suppl 12 year: 2006 ident: 10.1016/j.transproceed.2011.09.043_bib16 article-title: Staging of hepatocellular cancer (HCC) before liver transplantation is suboptimal publication-title: Am J Transplant contributor: fullname: Freeman – volume: 42 start-page: 4585 year: 2010 ident: 10.1016/j.transproceed.2011.09.043_bib17 article-title: Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria publication-title: Transplant Proc doi: 10.1016/j.transproceed.2010.10.012 contributor: fullname: Macaron – volume: 14 start-page: 1107 year: 2008 ident: 10.1016/j.transproceed.2011.09.043_bib8 article-title: Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma publication-title: Liver Transpl doi: 10.1002/lt.21484 contributor: fullname: Toso – volume: 79 start-page: 483 year: 2005 ident: 10.1016/j.transproceed.2011.09.043_bib15 article-title: Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? publication-title: Transplantation doi: 10.1097/01.TP.0000152801.82734.74 contributor: fullname: Sotiropoulos – volume: 33 start-page: 1080 year: 2001 ident: 10.1016/j.transproceed.2011.09.043_bib10 article-title: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis publication-title: Hepatology doi: 10.1053/jhep.2001.23561 contributor: fullname: Jonas – volume: 362 start-page: 1907 year: 2003 ident: 10.1016/j.transproceed.2011.09.043_bib4 article-title: Hepatocellularcarcinoma publication-title: Lancet contributor: fullname: Lovet – volume: 12 start-page: 410 year: 2006 ident: 10.1016/j.transproceed.2011.09.043_bib13 article-title: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells publication-title: Nat Med doi: 10.1038/nm1377 contributor: fullname: Lee – volume: 340 start-page: 745 year: 1999 ident: 10.1016/j.transproceed.2011.09.043_bib3 article-title: Rising incidence of hepatocellular carcinoma in the United States publication-title: N Engl J Med doi: 10.1056/NEJM199903113401001 contributor: fullname: El-Serag – volume: 42 start-page: 1208 year: 2005 ident: 10.1016/j.transproceed.2011.09.043_bib14 article-title: Management of hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.20933 contributor: fullname: Bruix – volume: 359 start-page: 1995 year: 2008 ident: 10.1016/j.transproceed.2011.09.043_bib11 article-title: Gene expression in fixed tissues and outcome in hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0804525 contributor: fullname: Hoshida – volume: 14 start-page: 419 year: 2008 ident: 10.1016/j.transproceed.2011.09.043_bib12 article-title: Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-0523 contributor: fullname: Jiang – volume: 334 start-page: 693 year: 1996 ident: 10.1016/j.transproceed.2011.09.043_bib6 article-title: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis publication-title: N Engl J Med doi: 10.1056/NEJM199603143341104 contributor: fullname: Mazzaferro – volume: 55 start-page: 74 year: 2005 ident: 10.1016/j.transproceed.2011.09.043_bib1 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.55.2.74 contributor: fullname: Parkin – volume: 228 start-page: 479 year: 1998 ident: 10.1016/j.transproceed.2011.09.043_bib9 article-title: Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome publication-title: Ann Surg doi: 10.1097/00000658-199810000-00005 contributor: fullname: Klintmalm – volume: 42 start-page: 1208 year: 2005 ident: 10.1016/j.transproceed.2011.09.043_bib5 article-title: Management of hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.20933 contributor: fullname: Bruix |
SSID | ssj0004243 |
Score | 2.0938318 |
Snippet | Abstract Background It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these... It is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients would have low... BACKGROUNDIt is likely that some patients whose tumor burdens exceed the current transplant criteria have favorable tumor biology, and that these patients... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 3813 |
SubjectTerms | alpha-Fetoproteins - analysis Biological and medical sciences Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Cell Differentiation Cell Proliferation Disease-Free Survival Female Fundamental and applied biological sciences. Psychology Fundamental immunology Gastroenterology. Liver. Pancreas. Abdomen Humans Kaplan-Meier Estimate Liver Neoplasms - pathology Liver Neoplasms - surgery Liver Transplantation - adverse effects Liver, biliary tract, pancreas, portal circulation, spleen Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Neoplasm Invasiveness Neoplasm Recurrence, Local Ohio Patient Selection Proportional Hazards Models Retrospective Studies Risk Assessment Risk Factors ROC Curve Severity of Illness Index Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the digestive system Time Factors Tissue, organ and graft immunology Treatment Outcome Tumor Burden Tumors |
Title | Rate of Tumor Growth Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation in Patients Beyond Milan or UCSF Criteria |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0041134511012620 https://dx.doi.org/10.1016/j.transproceed.2011.09.043 https://www.ncbi.nlm.nih.gov/pubmed/22172852 https://search.proquest.com/docview/911950125 |
Volume | 43 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEF5CSqFQSpP0obYxcyg5RYm0O5KlQw-uies-EkxqQ26LtJKISy0ZSz740h_QX93ZXclOKIFCb0LSokXz3N1vvmHsfUZu30uziCyNrAkxQJeyEOXGqac8JRJUBkRzeRWOZ_jlJrjZY8OuFkbDKlvfb3268dbtnfP2b54v53Nd44u-LzS_FjnZkOt1O1IwIp0--7WDeSDvkHO-q9_uiEcNxqsxBOI2UrR0nvGZh-KhIPV0mdT06wrb8-LhpNQEp9Fz9qzNKmFgJ37A9vLykB0NSlpRLzZwAgbnaTbQD9njj93VycTyVm9OYborw6pPzYAto_XmiP2-powUqgKm60W1gk-0dG9uYbLShzxNDdd6z95UDep3xhTgmkofCGiEKwx1s6KyWiQw0O3I4ZsGgoDlVP-Z2MKnEuYlTCzDaw22qAYu5_QY6HOz4fcR6JYM2lhesNnoYjocu20TB1dhiI0rChGkKHgWeCrCKKMVDPp9X6FKg4Q8SKYo41Gh4EqpPIlT0Y-KLM6KkK65Rxr0ku2XVZm_ZoB5hEXBeT8VBWKWR3GQBkWii-JRKS4cJjqpyaXl6pAdiO2HvCtrqWUtvViSrB3W7wQsu2pU8p953RpzLX1Zc-nJvxTOYR-2I-_prKRw9E9f7t3Tp-2keSCQfKnvMOgUTJLVa8klZV6taxmb9r2UnDrslVW83WDTcizgb_5zdm_ZE7N_bqA779h-s1rnx5SANWnPWFiPPRp8_jq--gOpqDIZ |
link.rule.ids | 315,786,790,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5VRQgkhKDlYR5lDqinurV3x4594BAiQoCkikoi9bay17YIInYUO4dc-AH8amZ37YQKVULiZtleeeV57u433zD2NiO376VZRJZG1oQYoEtZiHLj1FOeEgkqA6KZXIajOX6-Dq4P2KCrhdGwytb3W59uvHV756L9mxerxULX-KLvC82vRU425LRuv6PTed2_4fznHueBvIPO-a5-vWMeNSCvxjCI21DR8nnG5x6K26LUg1VS078rbNOL27NSE52Gj9jDNq2Evp35Y3aQl0fsuF_Sknq5hVMwQE-zg37E7r7vrk6nlrh6ewazfR1WfWYG7Citt8fs1xWlpFAVMNssqzV8pLV78w2ma33K09RwpTftTdmgfmdEEa6p9ImAhrjCQHcrKqtlAn3djxzGGgkCllT9R2Irn0pYlDC1FK812KoamCzoMdDn5oOvQ9A9GbS1PGHz4YfZYOS2XRxchSE2rihEkKLgWeCpCKOMljDo93yFKg0SciGZopRHhYIrpfIkTkUvKrI4K0K65h6p0FN2WFZl_pwB5hEWBee9VBSIWR7FQRoUia6KR6W4cJjopCZXlqxDdii27_JPWUsta-nFkmTtsF4nYNmVo5IDzevWmmvpy5pLT_6lcQ57txt5Q2klxaN_-vLJDX3aTZoHAsmZ-g6DTsEkmb2WXFLm1aaWsenfS9mpw55ZxdsPNj3HAv7iP2f3ht0bzSZjOf50-eUlu2820w2O5xU7bNab_DVlY016YqztN2XrM6s |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rate+of+Tumor+Growth+Predicts+Recurrence+of+Hepatocellular+Carcinoma+After+Liver+Transplantation+in+Patients+Beyond+Milan+or+UCSF+Criteria&rft.jtitle=Transplantation+proceedings&rft.au=Hanouneh%2C+I.A.&rft.au=Macaron%2C+C.&rft.au=Lopez%2C+R.&rft.au=Aucejo%2C+F.&rft.date=2011-12-01&rft.pub=Elsevier+Inc&rft.issn=0041-1345&rft.eissn=1873-2623&rft.volume=43&rft.issue=10&rft.spage=3813&rft.epage=3818&rft_id=info:doi/10.1016%2Fj.transproceed.2011.09.043&rft.externalDocID=S0041134511012620 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00411345%2FS0041134511X0012X%2Fcov150h.gif |